Innovative strategies to enhance access to HCV therapy

Affiliations

¹ The University of Chicago, Department of Medicine, Center for Liver Diseases, Chicago, IL 60637, USA.
² The University of Chicago, Department of Medicine, Center for Liver Diseases, Chicago, IL 60637, USA. Electronic address: aronsohn@uchicago.edu.

Comment

Hannah Roth et al. Lancet. 2025.

. 2025 May 17;405(10491):1722-1723.

doi: 10.1016/S0140-6736(25)00636-1. Epub 2025 May 8.

¹ The University of Chicago, Department of Medicine, Center for Liver Diseases, Chicago, IL 60637, USA.
² The University of Chicago, Department of Medicine, Center for Liver Diseases, Chicago, IL 60637, USA. Electronic address: aronsohn@uchicago.edu.

No abstract available

Conflict of interest statement

We declare no competing interests.

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
Cooke GS, Hung LM, Flower B, McCabe L, Hang VTK, Thu VT, Thuan DT, Dung NT, Phuong LT, Khoa DB, An NTC, Thach PN, Huong VTT, Bich DT, Tuyen NK, Ansari MA, Le Ngoc C, Quang VM, Phuong NTN, Thao LT, Tran NB, Kestelyn E, Kingsley C, Van Doorn R, Rahman M, Pett SL, Thwaites GE, Barnes E, Day JN, Chau NVV, Walker AS. Cooke GS, et al. Lancet. 2025 May 17;405(10491):1769-1780. doi: 10.1016/S0140-6736(25)00097-2. Epub 2025 May 8. Lancet. 2025. PMID: 40347964 Clinical Trial.